ARTICLE | Company News
Nautilus Neurosciences Inc., Tribute Pharmaceuticals sales and marketing update
November 22, 2010 8:00 AM UTC
Nautilus granted Tribute an exclusive license to develop and commercialize Cambia diclofenac powder in Canada. Tribute will be responsible for obtaining Canadian regulatory approval for the oral form...